Search

The primary aim of this study was to describe the use of the antiplatelet agent clopidogrel in pediatric tertiary care hospitals and to evaluate how it has changed over time. This retrospective cohort study of pediatric inpatients from 2000 to 2009 used the Pediatric Health Information System database (PHIS) which contains data from 42 U.S. tertiary care children's hospitals. Pharmacy billing codes were used to identify hospital admissions during which clopidogrel was administered. Patient demographics and concurrent use of other anticoagulant and antiplatelet drugs were collected. The International Classification of Diseases, ninth edition (ICD-9) codes were used to categorize admissions by potential indications for antiplatelet drugs and to identify bleeding and thrombotic events. From 2001 to 2009, clopidogrel use increased 15-fold, from 6 to 89.5 per 100,000 admissions. Patients with cardiac disease accounted for the largest proportion (75%), followed by stroke (9.4%) and Kawasaki disease (6.1%). Among those with cardiac disease, hypoplastic left heart syndrome (38%) and pulmonary artery anomalies (37%) were the most common. Aspirin was used concurrently during 52% of the admissions, enoxaparin during 9%, and warfarin during 5%. The use of clopidogrel is increasing rapidly among children with cardiovascular diseases. This population has a high risk of bleeding, thrombosis, and mortality. It therefore is imperative that future studies continue to evaluate the safety and efficacy of clopidogrel for these children.

Objective To evaluate clinical data and associated risk conditions of noncerebral systemic venous thromboembolism (VT), arterial thromboembolism (AT), and intracardiac thromboembolism (ICT) in neonates. Study design Data analysis of first systemic thromboembolism occurring in 75 live neonates (0-28 days), enrolled in the Italian Registry of Pediatric Thrombosis from neonatology centers between January 2007 and July 2013. Results Among 75 events, 41 (55%) were VT, 22 (29%) AT, and 12 (16%) ICT; males represented 65%, and 71% were preterm. In 19 (25%), thromboembolism was diagnosed on the first day of life. In this "early onset" group, prenatal-associated risk conditions (maternal/placental disease) were reported in 70% and inherited thrombophilia in 33%. Postnatal risk factors were present in 73%; infections and central vascular catheters in 56% and 54% VT, respectively, and in 67% ICT vs 27% AT ( Conclusions This report from the Registro Italiano Trombosi Infantili, although limited by representing an uncontrolled case series, can be used to develop future clinical trials on appropriate management and prevention of neonatal thrombosis, focusing on obstetrical surveillance and monitoring of critically ill neonates with vascular access. A thrombosis risk prediction rule specific for the neonatal population should be developed through prospective controlled studies.

Varicella zoster virus (VZV) is the only human virus known to replicate in arteries. After the acute infection, the virus persists in a noninfectious latent form in ganglia along the neuraxis, with intermittent periods of reactivation. Both primary and secondary reactivation are associated with stroke in children. These patients, regardless of the chosen treatment, have a high risk of recurrence, particularly those with worsening arterial stenosis. There are no specific therapy protocols for varicella-associated stroke in children, and the use of steroids or antiviral drugs is still controversial. We present a series of 4 children with stroke following varicella infection, with no recurrence and stable vascular stenosis at a mean follow-up of 18 months without steroid treatment. We also analyze possible correlations between anti-protein C, protein S and protein Z autoantibodies, and post-varicella arteriopathy.

The aim of this study was to assess the prevalence of inherited thrombophilia in ‘peri-neonatal arterial ischemic stroke’ (AIS), and its possible correlation with type of stroke and long-term neurological outcome. A cohort of twenty-four infants affected by AIS were analysed for risk factors, clinical and neuroradiological features, coagulation and thrombophilia profile and outcome. Two subgroups were considered, based on clinical presentation: infants symptomatic in the neonatal period, acute AIS (aAIS) and those with a delayed presentation (presumed peri-neonatal onset, pAIS). The mean follow-up on patients was 3 yr and 1 month (range 1–15 yr). Inherited thrombophilia, consisting of factor V Leiden and prothrombin G20210A mutations, protein C and/or protein S deficiencies, was detected in 28.6%. A significantly higher prevalence of inherited thrombophilia was observed in infants with pAIS compared with aAIS (Fisher’s exact test, P = 0.011). Infants with pAIS had a significantly worse neurological outcome with respect to aAIS (Fisher’s exact test, P = 0.014). Inherited thrombophilia was significantly higher in patients with a poor neurological outcome (Fisher’s exact test P = 0.002). Although the clinical presentation (aAIS vs. pAIS) was associated with future neurological disabilities, it is the thrombophilia but not the clinical presentation, which remains the only significant prognostic factor in the logistic regression analysis. Although preliminary, these data suggest an association of unfavourable neurological outcome and inherited prothrombotic defects in neonatal AIS. The higher prevalence of inherited thrombophilia identified in pAIS and the worse neurological outcome encourage further investigations in population-based studies.